116 related articles for article (PubMed ID: 16682193)
21. Property- and structure-guided discovery of a tetrahydroindazole series of interleukin-2 inducible T-cell kinase inhibitors.
Burch JD; Lau K; Barker JJ; Brookfield F; Chen Y; Chen Y; Eigenbrot C; Ellebrandt C; Ismaili MH; Johnson A; Kordt D; MacKinnon CH; McEwan PA; Ortwine DF; Stein DB; Wang X; Winkler D; Yuen PW; Zhang Y; Zarrin AA; Pei Z
J Med Chem; 2014 Jul; 57(13):5714-27. PubMed ID: 24918870
[TBL] [Abstract][Full Text] [Related]
22. Synthesis of potent and selective inhibitors of Candida albicans N-myristoyltransferase based on the benzothiazole structure.
Yamazaki K; Kaneko Y; Suwa K; Ebara S; Nakazawa K; Yasuno K
Bioorg Med Chem; 2005 Apr; 13(7):2509-22. PubMed ID: 15755653
[TBL] [Abstract][Full Text] [Related]
23. 4,5-dialkylsubstituted 2-imino-1,3-thiazolidine derivatives as potent inducible nitric oxide synthase inhibitors.
Ueda S; Terauchi H; Yano A; Matsumoto M; Kubo T; Kyoya Y; Suzuki K; Ido M; Kawasaki M
Bioorg Med Chem; 2004 Aug; 12(15):4101-16. PubMed ID: 15246088
[TBL] [Abstract][Full Text] [Related]
24. Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors.
Chen P; Norris D; Das J; Spergel SH; Wityak J; Leith L; Zhao R; Chen BC; Pitt S; Pang S; Shen DR; Zhang R; De Fex HF; Doweyko AM; McIntyre KW; Shuster DJ; Behnia K; Schieven GL; Barrish JC
Bioorg Med Chem Lett; 2004 Dec; 14(24):6061-6. PubMed ID: 15546730
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological evaluation of novel (4 or 5-aryl)pyrazolyl-indoles as inhibitors of interleukin-2 inducible T-cell kinase (ITK).
Velankar AD; Quintini G; Prabhu A; Weber A; Hunaeus G; Voland B; Wuest M; Orjeda C; Harel D; Varghese S; Gore V; Patil M; Gayke D; Herdemann M; Heit I; Zaliani A
Bioorg Med Chem; 2010 Jun; 18(12):4547-59. PubMed ID: 20472447
[TBL] [Abstract][Full Text] [Related]
26. Hit-to-lead studies on benzimidazole inhibitors of ITK: discovery of a novel class of kinase inhibitors.
Snow RJ; Abeywardane A; Campbell S; Lord J; Kashem MA; Khine HH; King J; Kowalski JA; Pullen SS; Roma T; Roth GP; Sarko CR; Wilson NS; Winters MP; Wolak JP; Cywin CL
Bioorg Med Chem Lett; 2007 Jul; 17(13):3660-5. PubMed ID: 17499505
[TBL] [Abstract][Full Text] [Related]
27. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.
Showalter HD; Sercel AD; Leja BM; Wolfangel CD; Ambroso LA; Elliott WL; Fry DW; Kraker AJ; Howard CT; Lu GH; Moore CW; Nelson JM; Roberts BJ; Vincent PW; Denny WA; Thompson AM
J Med Chem; 1997 Feb; 40(4):413-26. PubMed ID: 9046331
[TBL] [Abstract][Full Text] [Related]
28. Identification of potent type I MetAP inhibitors by simple bioisosteric replacement. Part 1: Synthesis and preliminary SAR studies of thiazole-4-carboxylic acid thiazol-2-ylamide derivatives.
Cui YM; Huang QQ; Xu J; Chen LL; Li JY; Ye QZ; Li J; Nan FJ
Bioorg Med Chem Lett; 2005 Aug; 15(16):3732-6. PubMed ID: 15993057
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and biological activity of N-aryl-2-aminothiazoles: potent pan inhibitors of cyclin-dependent kinases.
Misra RN; Xiao HY; Williams DK; Kim KS; Lu S; Keller KA; Mulheron JG; Batorsky R; Tokarski JS; Sack JS; Kimball SD; Lee FY; Webster KR
Bioorg Med Chem Lett; 2004 Jun; 14(11):2973-7. PubMed ID: 15125971
[TBL] [Abstract][Full Text] [Related]
30. Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase.
Gaillard P; Jeanclaude-Etter I; Ardissone V; Arkinstall S; Cambet Y; Camps M; Chabert C; Church D; Cirillo R; Gretener D; Halazy S; Nichols A; Szyndralewiez C; Vitte PA; Gotteland JP
J Med Chem; 2005 Jul; 48(14):4596-607. PubMed ID: 15999997
[TBL] [Abstract][Full Text] [Related]
31. Itk kinase inhibitors: initial efforts to improve the metabolical stability and the cell activity of the benzimidazole lead.
Moriarty KJ; Winters M; Qiao L; Ryan D; DesJarlis R; Robinson D; Cook BN; Kashem MA; Kaplita PV; Liu LH; Farrell TM; Khine HH; King J; Pullen SS; Roth GP; Magolda R; Takahashi H
Bioorg Med Chem Lett; 2008 Oct; 18(20):5537-40. PubMed ID: 18819794
[TBL] [Abstract][Full Text] [Related]
32. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series.
Song Y; Connor DT; Doubleday R; Sorenson RJ; Sercel AD; Unangst PC; Roth BD; Gilbertsen RB; Chan K; Schrier DJ; Guglietta A; Bornemeier DA; Dyer RD
J Med Chem; 1999 Apr; 42(7):1151-60. PubMed ID: 10197959
[TBL] [Abstract][Full Text] [Related]
33. Benzothiazole benzimidazole (S)-isothiazolidinone derivatives as protein tyrosine phosphatase-1B inhibitors.
Sparks RB; Polam P; Zhu W; Crawley ML; Takvorian A; McLaughlin E; Wei M; Ala PJ; Gonneville L; Taylor N; Li Y; Wynn R; Burn TC; Liu PC; Combs AP
Bioorg Med Chem Lett; 2007 Feb; 17(3):736-40. PubMed ID: 17097290
[TBL] [Abstract][Full Text] [Related]
34. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
Thompson AM; Murray DK; Elliott WL; Fry DW; Nelson JA; Showalter HD; Roberts BJ; Vincent PW; Denny WA
J Med Chem; 1997 Nov; 40(24):3915-25. PubMed ID: 9397172
[TBL] [Abstract][Full Text] [Related]
35. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
[TBL] [Abstract][Full Text] [Related]
36. Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor.
Rewcastle GW; Bridges AJ; Fry DW; Rubin JR; Denny WA
J Med Chem; 1997 Jun; 40(12):1820-6. PubMed ID: 9191958
[TBL] [Abstract][Full Text] [Related]
37. Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors.
Jung FH; Pasquet G; Lambert-van der Brempt C; Lohmann JJ; Warin N; Renaud F; Germain H; De Savi C; Roberts N; Johnson T; Dousson C; Hill GB; Mortlock AA; Heron N; Wilkinson RW; Wedge SR; Heaton SP; Odedra R; Keen NJ; Green S; Brown E; Thompson K; Brightwell S
J Med Chem; 2006 Feb; 49(3):955-70. PubMed ID: 16451062
[TBL] [Abstract][Full Text] [Related]
38. Discovery and structural modification of inhibitors of methionine aminopeptidases from Escherichia coli and Saccharomyces cerevisiae.
Luo QL; Li JY; Liu ZY; Chen LL; Li J; Qian Z; Shen Q; Li Y; Lushington GH; Ye QZ; Nan FJ
J Med Chem; 2003 Jun; 46(13):2631-40. PubMed ID: 12801227
[TBL] [Abstract][Full Text] [Related]
39. Discovery and initial SAR of 2-amino-5-carboxamidothiazoles as inhibitors of the Src-family kinase p56(Lck).
Wityak J; Das J; Moquin RV; Shen Z; Lin J; Chen P; Doweyko AM; Pitt S; Pang S; Shen DR; Fang Q; de Fex HF; Schieven GL; Kanner SB; Barrish JC
Bioorg Med Chem Lett; 2003 Nov; 13(22):4007-10. PubMed ID: 14592495
[TBL] [Abstract][Full Text] [Related]
40. 1,2-Benzisothiazol-3-one 1,1-dioxide inhibitors of human mast cell tryptase.
Combrink KD; Gülgeze HB; Meanwell NA; Pearce BC; Zulan P; Bisacchi GS; Roberts DG; Stanley P; Seiler SM
J Med Chem; 1998 Nov; 41(24):4854-60. PubMed ID: 9822554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
